Publications

Proceedings of the National Academy of Sciences of the United States of America

Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.

20-04-2010

Investigational new drugs

Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.

01-04-2010

Cancer research

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

15-02-2010

Clinical cancer research : an official journal of the American Association for Cancer Research

P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide.

01-01-2010

Cancer research

Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.

01-12-2009

Cancer treatment reviews

High-grade glioma mouse models and their applicability for preclinical testing.

01-12-2009

Molecular cancer therapeutics

Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.

01-12-2009

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.

01-11-2009

Clinical cancer research : an official journal of the American Association for Cancer Research

Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.

01-05-2009

Investigational new drugs

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.

01-02-2009

Current clinical pharmacology

Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).

01-01-2009

Clinical cancer research : an official journal of the American Association for Cancer Research

Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.

15-12-2008

Drug metabolism and disposition: the biological fate of chemicals

Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.

01-08-2008

Molecular cancer therapeutics

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.

01-08-2008

Molecular cancer therapeutics

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.

01-12-2007

The Journal of clinical investigation

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

01-11-2007

Biomedical chromatography : BMC

Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography.

01-11-2007

Clinical cancer research : an official journal of the American Association for Cancer Research

P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.

01-11-2007

Cancer cell

Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma.

01-10-2007

Proceedings of the National Academy of Sciences of the United States of America

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

17-07-2007

Biomedical chromatography : BMC

Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography.

01-07-2007

Investigational new drugs

Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.

01-02-2007

European journal of cancer (Oxford, England : 1990)

Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.

01-12-2006

Clinical cancer research : an official journal of the American Association for Cancer Research

Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.

15-10-2006

Expert review of neurotherapeutics

Blood-brain barrier and chemotherapeutic treatment of brain tumors.

01-08-2006

Cold Spring Harbor symposia on quantitative biology

Genotype-phenotype relationships in a mouse model for human small-cell lung cancer.

28-07-2006

The Journal of pharmacology and experimental therapeutics

Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.

01-07-2006

Cancer chemotherapy and pharmacology

The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.

01-06-2006

International journal of cancer

MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.

20-09-2005

Cancer chemotherapy and pharmacology

Metabolism of docetaxel in mice.

01-09-2005

Analytical and bioanalytical chemistry

Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry.

01-08-2005

Cancer research

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.

01-04-2005

Journal of mass spectrometry : JMS

A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry.

01-12-2004

Cancer research

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

15-08-2004

Cancer treatment reviews

Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?

01-08-2004

Investigational new drugs

Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.

01-08-2004

European journal of cancer (Oxford, England : 1990)

Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.

01-05-2004

Cancer chemotherapy and pharmacology

The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.

01-02-2004

Analytical biochemistry

Development and validation of a method to determine the unbound paclitaxel fraction in human plasma.

01-01-2004

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Bioanalysis of zosuquidar trihydrochloride (LY335979) in small volumes of human and murine plasma by ion-pairing reversed-phase high-performance liquid chromatography.

05-12-2003

British journal of cancer

P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo.

03-11-2003

Laboratory animals

Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples.

01-07-2003

Clinical cancer research : an official journal of the American Association for Cancer Research

Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.

01-07-2003

Cancer research

Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.

15-03-2003

Anti-cancer drugs

Metabolism of paclitaxel in mice.

01-03-2003

Anti-cancer drugs

Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma.

01-01-2003

Cancer research

Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.

01-11-2002

Cancer chemotherapy and pharmacology

A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.

01-07-2002

Molecular cancer therapeutics

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

01-04-2002

Cancer chemotherapy and pharmacology

Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.

01-02-2002

Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.

Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide.

Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.

High-grade glioma mouse models and their applicability for preclinical testing.

Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.

Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.

Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.

Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).

Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.

Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography.

P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.

Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma.

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography.

Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.

Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.

Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.

Blood-brain barrier and chemotherapeutic treatment of brain tumors.

Genotype-phenotype relationships in a mouse model for human small-cell lung cancer.

Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.

The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.

MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.

Metabolism of docetaxel in mice.

Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry.

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.

A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry.

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?

Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.

Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.

The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.

Development and validation of a method to determine the unbound paclitaxel fraction in human plasma.

Bioanalysis of zosuquidar trihydrochloride (LY335979) in small volumes of human and murine plasma by ion-pairing reversed-phase high-performance liquid chromatography.

P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo.

Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples.

Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.

Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.

Metabolism of paclitaxel in mice.

Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma.

Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.

A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.

This site uses cookies